EHBP1L1 and neoplasm: Tumor‐specific CD8+ T cells were generated by activating T cells with dendritic cells (DCs) pulsed with primary tumor lysates as previously described (Figure S2G, Supporting Information).[28, 29] EHBP1L1 silencing in primary tumor cells significantly enhanced the cytotoxicity of primary RCC tumor antigen‐activated CD8+ T cells to target tumor cells (Figure 2L).